Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sanofi
Biotech
M&A remains ‘top priority’ for pharmas in face of tariff threat
Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at least for the time being.
James Waldron
Apr 25, 2025 10:41am
Versant unveils new autoimmune biotech with $100M fundraise
Apr 24, 2025 8:00am
Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial
Apr 24, 2025 4:46am
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
Apr 23, 2025 6:35am
Sanofi pens $1.8B deal for 2 autoimmune, immunology bispecifics
Apr 17, 2025 8:51am
Sanofi's hopes for $1.1B Kymab drug dented after ph. 2 asthma fail
Apr 15, 2025 7:34am